Abilify Indication:

For the treatment of schizophrenia

Abilify Mechanism Of Action:

Abilify exhibits high affinity for dopamine D2 and D3, serotonin 5-HT1A and 5- HT2A receptors, moderate affinity for dopamine D4, serotonin 5-HT2C and 5-HT7, alpha1-adrenergic and histamine H1 receptors and moderate affinity for the serotonin reuptake pump. Abilify has no appreciable affinity for cholinergic muscarinic receptors. Abilify functions as a partial agonist at the dopamine D2 and the serotonin 5-HT1A receptors, and as an antagonist at serotonin 5-HT2A receptor.

Abilify Drug Interactions:

Carbamazepine Carbamazepine decreases the effect of aripiprazole
Itraconazole The imidazole increases the effect of aripiprazole
Ketoconazole The imidazole increases the effect of aripiprazole
Dihydroquinidine barbiturate Quinidine increases the effect and toxicity of aripiprazole
Quinidine Quinidine increases the effect and toxicity of aripiprazole
Quinidine barbiturate Quinidine increases the effect and toxicity of aripiprazole

Abilify Food Interactions:

Take without regard to meals.
Food has no significant effect on absorption.
Avoid alcohol (possible additive effect to CNS).

Abilify Generic Name:

Synonyms:

  • OPC-14597
  • OPC 31

Drug Type:

Small Molecule; Approved; Investigational

Absorption:

Not Available

Toxicity (Overdose):

Not Available

Protein Binding:

>99%

Biotransformation:

Hepatic.

Half Life:

75-146 hours

Dosage Forms of Abilify:

Tablet Oral

Chemical IUPAC Name:

7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one

Organisms Affected:

Humans and other mammals

Abilify to general, pharmacology

General, pharmacology..